Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma

BACKGROUND. Relapsed or refractory mantle cell lymphoma (MCL) has a poor prognosis. The best outcome is achieved in patients who have a partial or complete response to salvage treatment and proceed to allogeneic stem cell transplant. PATIENTS AND METHODS. Twenty‐one patients were given a combination...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Lee, Hun Ju, Romaguera, Jorge E., Feng, Lei, Desai, Aakash P., Zhang, Liang, Fanale, Michelle, Samaniego, Felipe, Hagemeister, Fredrick B., Fayad, Luis E., Rodriguez, Maria A., Medeiros, Jeffrey L., Hartig, Kimberly, Nomie, Krystle, Ahmed, Makhdum, Badillo, Maria, Ye, Haige, Oki, Yasuhiro, Lin, Pei, Nastoupil, Loretta, Westin, Jason, Wang, Michael
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2017
Matèries:
Hematologic Malignancies
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5423503/
https://ncbi.nlm.nih.gov/pubmed/28408615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0328
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars